Guardant Health’s Shield colorectal cancer screening test volume more than tripled year over year in the third quarter, reaching 83,000 tests compared to 24,000 a year ago.
Higher test volume helped drive up revenue 36 percent year over year as the company reported third-quarter revenue of $361.0 million on Nov. 5, beating the consensus Wall Street estimate of $350.7 million. Guardant raised its full-year revenue outlook in response.
Screening revenue was $67.6 million, more than double $24.1 million in Q3 2025. Oncology revenue was $231.3 million, up 25 percent from $184.4 million in Q3 2025. Oncology test volume grew to 117,000, up 58 percent year over year.
Biopharma and data revenue grew 8 percent to $59.0 million from $54.7 million a year ago. Licensing and other revenue was $3.1 million.
Guardant’s net loss for the quarter was $124.4 million, or $0.93 per share, compared with a net loss of $92.7 million, or $0.74 per share, in Q3 2025. Adjusted EPS was $0.29 loss per share, beating the consensus Wall Street estimate of $0.31 loss per share.
R&D expense was $100.8 million, up 12 percent from $90.0 million a year ago. SG&A expenses were $268.1 million, up 48 percent from $180.6 million a year ago, with the increase attributed to commercial infrastructure expansion and marketing to support Shield and oncology growth.
Guardant ended the quarter with $1.02 billion in cash and cash equivalents and $119.2 million in restricted cash.
For the full year, Guardant now expects revenue of $1.36 billion to $1.37 billion, representing growth of 38 percent to 40 percent, up from prior guidance of $1.34 billion to $1.36 billion. Full-year Shield volume guidance was raised to 285,000 to 290,000 tests, with screening revenue now expected in the range of $233 million to $238 million.
